ArticleBMC cancer2026
Inhibition of nuclear import suppresses androgen receptor action and overcomes resistance in prostate cancer.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Natural Products in Prostate Cancer: Crosstalk Among the Gut Microbiome, Androgen Receptor Signaling, and Epigenetic Regulation.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundAndrogen deprivation and androgen receptor (AR) antagonists are essential treatments for prostate cancers in the clinic. However, after an initially effective response, most tumors become resistant to androgen deprivation therapies. Resistance often arises from AR mutations, resulting in ligand-independent activation and nuclear translocation of AR.
methodsThis study investigated the effects of nuclear import inhibition on AR signaling and enzalutamide resistance. We utilized nuclear import inhibitors (importazole and ivermectin) and KPNB1 (importin β) knockdown in prostate cancer cell models. We assessed AR subcellular localization, AR-dependent transactivation (transcriptional activity), cell viability and apoptosis in cells expressing wild-type AR, the AR-F876L mutant, or the constitutively active AR splice variant AR-V7.
resultsInhibition of nuclear import suppressed AR-dependent transactivation, increased cytoplasmic AR, and enhanced the action of enzalutamide by promoting the apoptosis of prostate cancer cells. While enzalutamide became an AR agonist in cells harboring the mutated AR (F876L), inhibition of nuclear import inhibited enzalutamide-induced nuclear localization and transactivation of the mutated AR and reduced the viability of AR-F876L-expressing cells. Both importazole and ivermectin attenuated the transcriptional activation induced by a constitutively active AR splice variant (AR-V7), while enzalutamide showed no effect.
conclusionInhibition of nuclear import can overcome enzalutamide resistance and may serve as a novel strategy for prostate cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.